Liang Hao, Zhu Yu, Wu Ya-Kun
Department of Hepatobiliary Surgery, Suining Central Hospital, Suining, China.
Front Oncol. 2023 May 18;13:1135324. doi: 10.3389/fonc.2023.1135324. eCollection 2023.
The incidence of ampulla of Vater carcinoma, a type of periampullary cancer, has been increasing at an annual percentage rate of 0.9%. However, patients with ampulla of Vater carcinoma have quite different prognoses due to the heterogeneities of the tissue origin of this carcinoma. In addition to TNM staging, histological subtypes and molecular features of ampulla of Vater carcinoma are the key factors for predicting the clinical outcomes of patients. Fortunately, with the development of testing technology, information on the histological subtypes and molecular features of ampulla of Vater carcinoma is increasingly being analyzed in-depth. Patients with the pancreaticobiliary subtype have shorter survival times. In immunohistochemical examination, high cutoff values of positive MUC1 staining can be used to accurately predict the outcome of patients. Mutant , , negative expression, and microsatellite stability are related to poor prognosis, while the clinical value of mutations is limited for prognosis. Testing the histological subtypes and molecular characteristics of ampulla of Vater carcinoma not only is the key to prognosis analysis but also provides extra information for targeted treatment to improve the clinical outcomes of patients.
壶腹癌是一种壶腹周围癌，其发病率正以每年0.9%的速度上升。然而，由于该癌组织起源的异质性，壶腹癌患者的预后差异很大。除TNM分期外，壶腹癌的组织学亚型和分子特征是预测患者临床结局的关键因素。幸运的是，随着检测技术的发展，关于壶腹癌组织学亚型和分子特征的信息越来越多地得到深入分析。胰胆管亚型的患者生存时间较短。在免疫组化检查中，MUC1染色阳性的高临界值可用于准确预测患者的预后。突变、、阴性表达和微卫星稳定性与预后不良有关，而突变对预后的临床价值有限。检测壶腹癌的组织学亚型和分子特征不仅是预后分析的关键，还为靶向治疗提供额外信息以改善患者的临床结局。
